Steve Kirsch's newsletter

Share this post

Eiger announces Interferon Lambda results this morning before the market opens

stevekirsch.substack.com

Eiger announces Interferon Lambda results this morning before the market opens

I'm pretty sure this drug, which is extremely safe, will have extremely positive results against COVID if it is given early in the disease.

Steve Kirsch
Mar 17, 2022
387
131
Share this post

Eiger announces Interferon Lambda results this morning before the market opens

stevekirsch.substack.com

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022.

The call is at 5:30 AM Pacific / 8:30 AM Eastern and is open to the public.

I’ll make two predictions:

  1. The drug will have remarkable efficacy against COVID if it was administered early, at the first sign of symptoms. This is based on the trial in Toronto as well as other things I’ve heard. This is likely to be the best drug that the TOGETHER trial has ever tested, even better than fluvoxamine.

  2. The NIH will find a way to complete ignore this drug even though it has a fantastic side effect profile (virtually nil) and is more effective than monoclonals which were approved (greater reduction in viral loads seen)..

We’ll see Thursday morning how accurate my predictions were.

131
Share this post

Eiger announces Interferon Lambda results this morning before the market opens

stevekirsch.substack.com
131 Comments
Clint Stevens
Mar 23, 2022

It will fight cancer also: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925029/

Expand full comment
Reply
Cathleen Manny
Mar 21, 2022

You’re ‘pretty sure...’?! I find it strange that you just throw a drug out there and describe it as something rather sensational. Do you own stock in this drug company or something? No, thanks.

Expand full comment
Reply
129 more comments…
TopNewCommunity

No posts

Ready for more?

© 2023 Steve Kirsch
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing